Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

Phase 1 Completed 21 enrolled H. Lee Moffitt Cancer Center and Research Institute CG Oncology, Inc. · collab Richard M. Shulze Family Foundation · collab

NaSingle-groupOpen-labelTreatment

Summary

Investigators will evaluate the safety and efficacy of combination neoadjuvant therapy using intravesical CG0070 and IV Nivolumab in cisplatin ineligible patients with Muscle Invasive Bladder Cancer (MIBC).

Timeline

Start: 2020-10-26
Primary completion: 2024-07-25
Completion: 2024-07-25

Publications

Results Li R, Villa NY, Yu X, Johnson JO, Borjas G, Dhillon J, Moran-Segura CM, Kim Y, Francis N, Dorman D, Powers JJ, Sexton WJ, Spiess PE, Poch MA, Zemp L, Gilbert SM, Zhang J, Pow-Sang JM, Anderson ARA, Li T, Wang X, Grass GD, Burke JM, Dinney CPN, Rodriguez PC, Jain RK, Mule JJ, Conejo-Garcia JR. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nat Med. 2025 Jan;31(1):176-188. doi: 10.1038/s41591-024-03324-9. Epub 2024 Nov 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cretostimogene Grenadenorepvec	Unknown	1e+12 unknown	Other
Subject	Nivolumab	Monoclonal antibody	480 mg	Intravenous

Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

Summary

Timeline

Publications

Drugs

Indications